Cargando…

Botulinum Toxin for the Treatment of Hand Tremor

The aim of this study is to review our longitudinal experience with onabotulinumtoxinA (onaBoNT-A) injections for medically refractory hand tremor. We performed a retrospective review of our database of patients treated with onaBoNT-A for hand tremor evaluated between 2010 and 2018 in at least 2 ses...

Descripción completa

Detalles Bibliográficos
Autores principales: Niemann, Nicki, Jankovic, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070882/
https://www.ncbi.nlm.nih.gov/pubmed/30029483
http://dx.doi.org/10.3390/toxins10070299
_version_ 1783343756145065984
author Niemann, Nicki
Jankovic, Joseph
author_facet Niemann, Nicki
Jankovic, Joseph
author_sort Niemann, Nicki
collection PubMed
description The aim of this study is to review our longitudinal experience with onabotulinumtoxinA (onaBoNT-A) injections for medically refractory hand tremor. We performed a retrospective review of our database of patients treated with onaBoNT-A for hand tremor evaluated between 2010 and 2018 in at least 2 sessions with follow-up. The majority were injected into the forearm flexors (FF), although treatment was individualized. During the specified period, 91 patients (53 essential tremor, 31 dystonic tremor, 6 Parkinson’s disease tremor, and 1 cerebellar outflow tremor) met our inclusion criteria. The mean age (SD) was 64.8 years (12.8), and mean duration of follow-up was 29.6 months (25.1) with mean of 7.7 (6.3) treatment visits. FF were injected in 89 (97.8%) patients, exclusively in 74 (81.3%), and 15 (16.5%) were injected in FF and other muscles. EMG guidance was used in 5 patients (5.5%). On a 0–4 “peak effect” rating scale (0 = no effect, 4 = marked improvement in severity and function), 80.2% and 85.7% of patients reported moderate or marked improvement (score 3 or 4) at their first and last follow-up visit, respectively. There was no statistically significant difference in the outcomes between first and last visit: average “peak effect” rating score (3.2 versus 3.4), “global” rating score (3.0 versus 3.2), latency of response (4.5 versus 3.8 days), and total duration of response (12.7 versus 12.8 weeks), except onaBoNT-A dose (65.0 versus 78.6 U/limb, p = 0.002). Of 1095 limb injections, there were 134 (12.2%) non-disabling and transient (mean 36 days) adverse events (132 limb weakness, 2 pain). OnaBoNT-A injections are safe and effective in the treatment of hand tremor.
format Online
Article
Text
id pubmed-6070882
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60708822018-08-09 Botulinum Toxin for the Treatment of Hand Tremor Niemann, Nicki Jankovic, Joseph Toxins (Basel) Article The aim of this study is to review our longitudinal experience with onabotulinumtoxinA (onaBoNT-A) injections for medically refractory hand tremor. We performed a retrospective review of our database of patients treated with onaBoNT-A for hand tremor evaluated between 2010 and 2018 in at least 2 sessions with follow-up. The majority were injected into the forearm flexors (FF), although treatment was individualized. During the specified period, 91 patients (53 essential tremor, 31 dystonic tremor, 6 Parkinson’s disease tremor, and 1 cerebellar outflow tremor) met our inclusion criteria. The mean age (SD) was 64.8 years (12.8), and mean duration of follow-up was 29.6 months (25.1) with mean of 7.7 (6.3) treatment visits. FF were injected in 89 (97.8%) patients, exclusively in 74 (81.3%), and 15 (16.5%) were injected in FF and other muscles. EMG guidance was used in 5 patients (5.5%). On a 0–4 “peak effect” rating scale (0 = no effect, 4 = marked improvement in severity and function), 80.2% and 85.7% of patients reported moderate or marked improvement (score 3 or 4) at their first and last follow-up visit, respectively. There was no statistically significant difference in the outcomes between first and last visit: average “peak effect” rating score (3.2 versus 3.4), “global” rating score (3.0 versus 3.2), latency of response (4.5 versus 3.8 days), and total duration of response (12.7 versus 12.8 weeks), except onaBoNT-A dose (65.0 versus 78.6 U/limb, p = 0.002). Of 1095 limb injections, there were 134 (12.2%) non-disabling and transient (mean 36 days) adverse events (132 limb weakness, 2 pain). OnaBoNT-A injections are safe and effective in the treatment of hand tremor. MDPI 2018-07-19 /pmc/articles/PMC6070882/ /pubmed/30029483 http://dx.doi.org/10.3390/toxins10070299 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Niemann, Nicki
Jankovic, Joseph
Botulinum Toxin for the Treatment of Hand Tremor
title Botulinum Toxin for the Treatment of Hand Tremor
title_full Botulinum Toxin for the Treatment of Hand Tremor
title_fullStr Botulinum Toxin for the Treatment of Hand Tremor
title_full_unstemmed Botulinum Toxin for the Treatment of Hand Tremor
title_short Botulinum Toxin for the Treatment of Hand Tremor
title_sort botulinum toxin for the treatment of hand tremor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070882/
https://www.ncbi.nlm.nih.gov/pubmed/30029483
http://dx.doi.org/10.3390/toxins10070299
work_keys_str_mv AT niemannnicki botulinumtoxinforthetreatmentofhandtremor
AT jankovicjoseph botulinumtoxinforthetreatmentofhandtremor